FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136809747> ?p ?o ?g. }

• W3136809747 endingPage "57" @default.
• W3136809747 startingPage "43" @default.
• W3136809747 abstract "Chondroitin sulfate is used for osteoarthritis combination therapy. It should be taken into account that the structure and properties of polysaccharides included in chondroitin sulfate, as well as the raw materials used for its production, have a significant effect on its absorption, bioavailability, and, as a consequence, on the safety and efficacy of orally administered products. The aim of the study was to assess toxic properties, local irritant effect, immunotoxicity, basic pharmacokinetic parameters, and therapeutic efficacy of the new Chondroitin sulfate product (produced by Federal State Unitary Enterprise “Moscow Endocrine Plant”, Russia) as compared to Structum (produced by “Pierre Fabre Medicament Production”, France). Materials and methods : White Giant rabbits were used in the experiments. Toxicity, immunotoxicity and local irritation effects of the products were assessed following daily oral administration at the dose of 168 mg/kg (about 6 Maximum Recommended Therapeutic Doses) to male and female rabbits for 28 days. The follow-up period was 14 days. The pharmacokinetic study included blood sampling on days 1‒2 of the experiment, complete blood count and blood chemistry tests were performed on days 28 and 43. After killing the animals, pathomorphological and histological examinations were performed on their organs and tissues. Therapeutic efficacy was studied in an osteoarthritis model made by cruciate ligament transaction in rabbits. The animals received therapy at doses of 16.8 mg/kg, 33.6 mg/kg, and 67.2 mg/kg for 56 days starting from day 8 after the pathology induction. Results : the medicines had no toxic, local irritant, or immunotoxic effect. The NOAEL was established at 168 mg/kg. The study demonstrated the comparability of the pharmacokinetic profiles of the studied products following single oral administration. The maximum concentration of the active ingredient (C max = 79 ± 6 μg/mL—Chondroitin sulfate; C max = 71 ± 4 μg/mL— Structum) in blood plasma was observed within 3–4 hours after administration. A decrease in the severity of cartilage structural damage was observed for the doses of 33.6 mg/kg and 67.2 mg/kg. The results of quantitative determination of sulfated glycosaminoglicans in the proteoglycans of the cartilage articular surface in the animals with osteoarthritis demonstrated an increase in the level of sulfated glycosaminoglicans in the groups treated with the maximum doses of the studied products, as compared to the other groups. Conclusions : the obtained data confirm that the test product has a favourable safety profile, and therapeutic (chondroprotective) effect. All the tested properties of Chondroitin sulfate were comparable to those of Structum." @default.
• W3136809747 created "2021-03-29" @default.
• W3136809747 creator A5006820791 @default.
• W3136809747 creator A5009229342 @default.
• W3136809747 creator A5015020588 @default.
• W3136809747 creator A5051319556 @default.
• W3136809747 creator A5052412286 @default.
• W3136809747 creator A5067929631 @default.
• W3136809747 creator A5081467862 @default.
• W3136809747 creator A5083970052 @default.
• W3136809747 creator A5086328388 @default.
• W3136809747 creator A5086361460 @default.
• W3136809747 date "2021-03-16" @default.
• W3136809747 modified "2023-10-05" @default.
• W3136809747 title "Preclinical Study of the Efficacy and Safety of Chondroitin Sulfate" @default.
• W3136809747 cites W1564418536 @default.
• W3136809747 cites W1975756026 @default.
• W3136809747 cites W1981118422 @default.
• W3136809747 cites W2029720037 @default.
• W3136809747 cites W2032255522 @default.
• W3136809747 cites W2042074652 @default.
• W3136809747 cites W2050019946 @default.
• W3136809747 cites W2056742992 @default.
• W3136809747 cites W2075422591 @default.
• W3136809747 cites W2079419761 @default.
• W3136809747 cites W2113853411 @default.
• W3136809747 cites W2124790232 @default.
• W3136809747 cites W2137431472 @default.
• W3136809747 cites W2141793986 @default.
• W3136809747 cites W2154357986 @default.
• W3136809747 cites W2162435517 @default.
• W3136809747 cites W2337039355 @default.
• W3136809747 cites W2341217973 @default.
• W3136809747 cites W2792218067 @default.
• W3136809747 cites W3014779043 @default.
• W3136809747 cites W4292542165 @default.
• W3136809747 doi "https://doi.org/10.30895/2312-7821-2021-9-1-43-57" @default.
• W3136809747 hasPublicationYear "2021" @default.
• W3136809747 type Work @default.
• W3136809747 sameAs 3136809747 @default.
• W3136809747 citedByCount "0" @default.
• W3136809747 crossrefType "journal-article" @default.
• W3136809747 hasAuthorship W3136809747A5006820791 @default.
• W3136809747 hasAuthorship W3136809747A5009229342 @default.
• W3136809747 hasAuthorship W3136809747A5015020588 @default.
• W3136809747 hasAuthorship W3136809747A5051319556 @default.
• W3136809747 hasAuthorship W3136809747A5052412286 @default.
• W3136809747 hasAuthorship W3136809747A5067929631 @default.
• W3136809747 hasAuthorship W3136809747A5081467862 @default.
• W3136809747 hasAuthorship W3136809747A5083970052 @default.
• W3136809747 hasAuthorship W3136809747A5086328388 @default.
• W3136809747 hasAuthorship W3136809747A5086361460 @default.
• W3136809747 hasBestOaLocation W31368097471 @default.
• W3136809747 hasConcept C102652120 @default.
• W3136809747 hasConcept C105702510 @default.
• W3136809747 hasConcept C112705442 @default.
• W3136809747 hasConcept C126322002 @default.
• W3136809747 hasConcept C142724271 @default.
• W3136809747 hasConcept C153074725 @default.
• W3136809747 hasConcept C181389837 @default.
• W3136809747 hasConcept C203014093 @default.
• W3136809747 hasConcept C204787440 @default.
• W3136809747 hasConcept C2776164576 @default.
• W3136809747 hasConcept C2777063393 @default.
• W3136809747 hasConcept C2779553658 @default.
• W3136809747 hasConcept C29730261 @default.
• W3136809747 hasConcept C71924100 @default.
• W3136809747 hasConcept C98274493 @default.
• W3136809747 hasConceptScore W3136809747C102652120 @default.
• W3136809747 hasConceptScore W3136809747C105702510 @default.
• W3136809747 hasConceptScore W3136809747C112705442 @default.
• W3136809747 hasConceptScore W3136809747C126322002 @default.
• W3136809747 hasConceptScore W3136809747C142724271 @default.
• W3136809747 hasConceptScore W3136809747C153074725 @default.
• W3136809747 hasConceptScore W3136809747C181389837 @default.
• W3136809747 hasConceptScore W3136809747C203014093 @default.
• W3136809747 hasConceptScore W3136809747C204787440 @default.
• W3136809747 hasConceptScore W3136809747C2776164576 @default.
• W3136809747 hasConceptScore W3136809747C2777063393 @default.
• W3136809747 hasConceptScore W3136809747C2779553658 @default.
• W3136809747 hasConceptScore W3136809747C29730261 @default.
• W3136809747 hasConceptScore W3136809747C71924100 @default.
• W3136809747 hasConceptScore W3136809747C98274493 @default.
• W3136809747 hasIssue "1" @default.
• W3136809747 hasLocation W31368097471 @default.
• W3136809747 hasOpenAccess W3136809747 @default.
• W3136809747 hasPrimaryLocation W31368097471 @default.
• W3136809747 hasRelatedWork W1555144605 @default.
• W3136809747 hasRelatedWork W1970245702 @default.
• W3136809747 hasRelatedWork W1970331292 @default.
• W3136809747 hasRelatedWork W1984317973 @default.
• W3136809747 hasRelatedWork W2004325424 @default.
• W3136809747 hasRelatedWork W2080955156 @default.
• W3136809747 hasRelatedWork W2379311614 @default.
• W3136809747 hasRelatedWork W2400119402 @default.
• W3136809747 hasRelatedWork W2606334551 @default.
• W3136809747 hasRelatedWork W2776273895 @default.
• W3136809747 hasVolume "9" @default.

• next